A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

What is the purpose of this study?

The purpose of this clinical trial is to evaluate the efficacy and safety of PF-0521377 (SAM-760), a drug that has the potential to improve cognition and decrease some behavioral symptoms associated with Alzheimer's disease.

Who is eligible?

We are looking for participants who:

-- have a diagnosis of Alzheimer's disease

-- are ages 60 or older

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are on stable doses of Aricept (donepezil)

-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)

Please see the attached study description for more information.